Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa | Zendy

Linnea Westerkam | Zendy; Kelly Jo Tackett | Zendy; Christopher Sayed | Zendy

Open Access

Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa

Author(s) -

Linnea Westerkam,

Kelly Jo Tackett,

Christopher Sayed

Publication year - 2021

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2021.0220

Subject(s) - infliximab , medicine , hidradenitis suppurativa , adalimumab , surgery , population , retrospective cohort study , dermatology , rheumatoid arthritis , tumor necrosis factor alpha , disease , environmental health

Although limited effective and affordable treatment options exist for hidradenitis suppurativa, recent studies describe the effectiveness of a medical therapy, infliximab, for the treatment of hidradenitis suppurativa. Cost-saving biosimilar alternatives have recently become available, but no data currently exist on their safety and effectiveness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research